Sitryx

Oxford, UK and Boston, MA - October 21, 2026 - Sitryx Therapeutics (

Sitryx Therapeutics, a biopharmaceutical company co-founded by Trinity's Professor Luke O'Neill has just announced positive results in a clinical trial of a new treatment for the inflammatory skin disease atopic dermatitis, which is commonly known as ecze

Proof of concept demonstrated for first-in-class oral therapy, addressing multiple aspects of atopic dermatitis pathology and with the potential t...

Proof of concept demonstrated for first-in-class oral therapy, addressing multiple aspects of atopic dermatitis pathology and with the potential to deliver lasting benefit to patientsSYX-5219 was safe and well-tolerated over the six-week treatment periodC

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity

Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly's Phase 1 clinic

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to Sitryx with the Company eligible to receive up to $570 million

INDIANAPOLIS and OXFORD, England, March 31, 2020/ PRNewswire/-- Eli Lilly and Company today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop diseas